Global Doxorubicin Market 2023-2027

Description

List of Tables

Technavio has been monitoring the doxorubicin market and is forecast to grow by $469.97 mn during 2022-2027, accelerating at a CAGR of 6.07% during the forecast period. Our report on the doxorubicin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of cancer cases, increasing product launches, and advancements in diagnostic methods.

Technavio's doxorubicin market is segmented as below:

By Formulation

Lyophilized powder
Doxorubicin injection

By End-user

Hospital pharmacy
Retail pharmacy
Online pharmacy
Others

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the introduction of precision cancer medicine in cancer as one of the prime reasons driving the doxorubicin market growth during the next few years. Also, increase in R&D of innovative biologics and increasing inorganic growth strategies by the vendors will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the doxorubicin market covers the following areas:

Doxorubicin market sizing
Doxorubicin market forecast
Doxorubicin market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading doxorubicin market vendors that include Aurobindo Pharma Ltd., Baxter International Inc., Cipla Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Meiji Holdings Co. Ltd., Merck KGaA, Mitsui and Co. Ltd., Novartis AG, Pfizer Inc., Pharmagen CZ s.r.o, Sun Pharmaceutical Industries Ltd., Synbias Pharma AG, TTY Biopharm Co. Ltd., Zydus Lifesciences Ltd., S. G. Biopharm Pvt. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the doxorubicin market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR75032

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Formulation
Exhibit 06: Executive Summary - Chart on Market Segmentation by End-user
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global doxorubicin market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global doxorubicin market 2017 - 2021 ($ million)
4.2 Formulation Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Formulation Segment 2017 - 2021 ($ million)
4.3 End-user Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - End-user Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Formulation

6.1 Market segments
Exhibit 30: Chart on Formulation - Market share 2022-2027 (%)
Exhibit 31: Data Table on Formulation - Market share 2022-2027 (%)
6.2 Comparison by Formulation
Exhibit 32: Chart on Comparison by Formulation
Exhibit 33: Data Table on Comparison by Formulation
6.3 Lyophilized powder - Market size and forecast 2022-2027
Exhibit 34: Chart on Lyophilized powder - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Lyophilized powder - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Lyophilized powder - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Lyophilized powder - Year-over-year growth 2022-2027 (%)
6.4 Doxorubicin injection - Market size and forecast 2022-2027
Exhibit 38: Chart on Doxorubicin injection - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Doxorubicin injection - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Doxorubicin injection - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Doxorubicin injection - Year-over-year growth 2022-2027 (%)
6.5 Market opportunity by Formulation
Exhibit 42: Market opportunity by Formulation ($ million)
Exhibit 43: Data Table on Market opportunity by Formulation ($ million)

7 Market Segmentation by End-user

7.1 Market segments
Exhibit 44: Chart on End-user - Market share 2022-2027 (%)
Exhibit 45: Data Table on End-user - Market share 2022-2027 (%)
7.2 Comparison by End-user
Exhibit 46: Chart on Comparison by End-user
Exhibit 47: Data Table on Comparison by End-user
7.3 Hospital pharmacy - Market size and forecast 2022-2027
Exhibit 48: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
Exhibit 49: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
Exhibit 50: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
Exhibit 51: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
7.4 Retail pharmacy - Market size and forecast 2022-2027
Exhibit 52: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
Exhibit 54: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
7.5 Online pharmacy - Market size and forecast 2022-2027
Exhibit 56: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)
7.6 Others - Market size and forecast 2022-2027
Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by End-user
Exhibit 64: Market opportunity by End-user ($ million)
Exhibit 65: Data Table on Market opportunity by End-user ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share by geography 2022-2027 (%)
Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Germany - Market size and forecast 2022-2027
Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.9 China - Market size and forecast 2022-2027
Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
9.10 UK - Market size and forecast 2022-2027
Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.11 Canada - Market size and forecast 2022-2027
Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity by geography
Exhibit 107: Market opportunity by geography ($ million)
Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Baxter International Inc.
Exhibit 115: Baxter International Inc. - Overview
Exhibit 116: Baxter International Inc. - Business segments
Exhibit 117: Baxter International Inc. - Key news
Exhibit 118: Baxter International Inc. - Key offerings
Exhibit 119: Baxter International Inc. - Segment focus
12.4 Cipla Ltd.
Exhibit 120: Cipla Ltd. - Overview
Exhibit 121: Cipla Ltd. - Business segments
Exhibit 122: Cipla Ltd. - Key news
Exhibit 123: Cipla Ltd. - Key offerings
Exhibit 124: Cipla Ltd. - Segment focus
12.5 Dr Reddys Laboratories Ltd.
Exhibit 125: Dr Reddys Laboratories Ltd. - Overview
Exhibit 126: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 127: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 128: Dr Reddys Laboratories Ltd. - Segment focus
12.6 Hikma Pharmaceuticals Plc
Exhibit 129: Hikma Pharmaceuticals Plc - Overview
Exhibit 130: Hikma Pharmaceuticals Plc - Business segments
Exhibit 131: Hikma Pharmaceuticals Plc - Key offerings
Exhibit 132: Hikma Pharmaceuticals Plc - Segment focus
12.7 Intas Pharmaceuticals Ltd.
Exhibit 133: Intas Pharmaceuticals Ltd. - Overview
Exhibit 134: Intas Pharmaceuticals Ltd. - Product / Service
Exhibit 135: Intas Pharmaceuticals Ltd. - Key offerings
12.8 Johnson and Johnson
Exhibit 136: Johnson and Johnson - Overview
Exhibit 137: Johnson and Johnson - Business segments
Exhibit 138: Johnson and Johnson - Key news
Exhibit 139: Johnson and Johnson - Key offerings
Exhibit 140: Johnson and Johnson - Segment focus
12.9 Meiji Holdings Co. Ltd.
Exhibit 141: Meiji Holdings Co. Ltd. - Overview
Exhibit 142: Meiji Holdings Co. Ltd. - Business segments
Exhibit 143: Meiji Holdings Co. Ltd. - Key news
Exhibit 144: Meiji Holdings Co. Ltd. - Key offerings
Exhibit 145: Meiji Holdings Co. Ltd. - Segment focus
12.10 Merck KGaA
Exhibit 146: Merck KGaA - Overview
Exhibit 147: Merck KGaA - Business segments
Exhibit 148: Merck KGaA - Key news
Exhibit 149: Merck KGaA - Key offerings
Exhibit 150: Merck KGaA - Segment focus
12.11 Novartis AG
Exhibit 151: Novartis AG - Overview
Exhibit 152: Novartis AG - Business segments
Exhibit 153: Novartis AG - Key offerings
Exhibit 154: Novartis AG - Segment focus
12.12 Pfizer Inc.
Exhibit 155: Pfizer Inc. - Overview
Exhibit 156: Pfizer Inc. - Product / Service
Exhibit 157: Pfizer Inc. - Key news
Exhibit 158: Pfizer Inc. - Key offerings
12.13 S. G. Biopharm Pvt. Ltd.
Exhibit 159: S. G. Biopharm Pvt. Ltd. - Overview
Exhibit 160: S. G. Biopharm Pvt. Ltd. - Product / Service
Exhibit 161: S. G. Biopharm Pvt. Ltd. - Key offerings
12.14 Sun Pharmaceutical Industries Ltd.
Exhibit 162: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 163: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 164: Sun Pharmaceutical Industries Ltd. - Key offerings
12.15 Synbias Pharma AG
Exhibit 165: Synbias Pharma AG - Overview
Exhibit 166: Synbias Pharma AG - Product / Service
Exhibit 167: Synbias Pharma AG - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 168: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 169: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 170: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 171: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 172: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 Zydus Lifesciences Ltd.
Exhibit 173: Zydus Lifesciences Ltd. - Overview
Exhibit 174: Zydus Lifesciences Ltd. - Business segments
Exhibit 175: Zydus Lifesciences Ltd. - Key offerings
Exhibit 176: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 177: Inclusions checklist
Exhibit 178: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 179: Currency conversion rates for US$
13.4 Research methodology
Exhibit 180: Research methodology
Exhibit 181: Validation techniques employed for market sizing
Exhibit 182: Information sources
13.5 List of abbreviations
Exhibit 183: List of abbreviations